Association between IL8RB C1208T mutation and risk of cancer: A pooled analysis based on 5299 cases and 6899 controls

Medicine (Baltimore). 2022 Feb 25;101(8):e28986. doi: 10.1097/MD.0000000000028986.

Abstract

Introduction: The CXC chemokines are unique cytokines that play a vital role in the progression of many cancers. Association between chemokine (C-X-C motif) receptor 2 (IL8RB) C1208T mutation and cancer risk remains incomprehensive.

Methods: We therefore utilized odds ratios and in silico analysis to explore the relationship of IL8RB polymorphism on risk to cancer. Furthermore, we adopted gene set enrichment analysis to investigate the IL8RB expression in prostate adenocarcinoma.

Results: A total of 14 case-control studies combined with 5299 cases and 6899 controls were included in our analysis. We revealed that individuals carrying TT genotype had an 14% increased cancer risk compared with those with TC + colon cancer (CC) genotype (odds ratio [OR] = 1.14, 95% CI = 1.05-1.25, P = .003, I2 = 35.6). Stratification analysis by race showed that East Asians with TT + TC genotype may have a 25% decreased cancer risk compared with control. Stratification analysis by cancer type revealed that individuals with TT genotype were associated with elevated risk of urinary cancer than control. The expression of IL8RB was attenuated in prostate adenocarcinoma.

Conclusions: IL8RB C1208T may be correlated with the risk of cancer, especially prostate adenocarcinoma.

MeSH terms

  • Adenocarcinoma / genetics*
  • Case-Control Studies
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Mutation / genetics
  • Polymorphism, Genetic
  • Polymorphism, Single Nucleotide
  • Prostatic Neoplasms / genetics*
  • Receptors, Interleukin-8B / genetics*
  • Risk Factors

Substances

  • CXCR2 protein, human
  • Receptors, Interleukin-8B